inflammatory bowel disease
Coverage of inflammatory bowel disease in the Nexus archive.
- Cell-type-resolved genetic variation shapes inflammatory bowel disease risk
A study published in Nature reveals that cell-type-specific genetic variants in inflammatory bowel disease (IBD) co-localize more frequently with genome-wide association study (GWAS) loci when analyzed at the cell-type level compared to the tissue level. Single-cell mapping of cis-expression quantitative trait loci (cis-eQTLs) identified distal, enhancer-enriched variants linked to IBD risk.
- Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
Sen. John Cornyn questioned AbbVie CEO Richard Gonzalez during a 2019 congressional hearing about the company's 136 patents on Humira, a drug with the same active molecule used to treat multiple conditions. Gonzalez defended the patents as 'innovations,' extending patent protection beyond the original 2016 expiry. The exchange highlights concerns about pharmaceutical companies leveraging patent portfolios to maintain monopolies.
- Black licorice compound shows promise against inflammatory bowel disease
Researchers developed a stem cell-based model of the human intestine to discover new IBD treatments and identified glycyrrhizin as a promising anti-inflammatory candidate. The compound reduced intestinal damage and cell death in lab-grown tissue and mice. This breakthrough may transform how new IBD treatments are discovered.
- STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
Johnson & Johnson's therapy for inflammatory bowel disease failed to show statistically meaningful improvement, but the company plans to advance it into late-stage testing. The therapy, combining Tremfya and Simponi, performed better than individual drugs in Phase 2b clinical trials. The company will focus on a growing subgroup of patients.